Merck to Acquire Prometheus Biosciences in $10.8 Billion Deal

Paul, Weiss is representing Merck in its all-cash $10.8 billion acquisition of Prometheus Biosciences, Inc. Merck will acquire the company for $200 per share under the deal, and expected to close in the third quarter of 2023, pending regulatory approvals and other conditions.

Prometheus is a clinical-stage biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment of immune-mediated diseases.

The Paul, Weiss team is led by Laura Turano, Scott Barshay and Jennifer Wang, and includes corporate partner Christodoulos Kaoutzanis; intellectual property partner Jonathan Ashtor and counsel Bonnie Chen; executive compensation partner Jarrett Hoffman; real estate partner Peter Fisch; tax counsel Alyssa Wolpin; litigation counsel Steven Herzog; and environmental counsel William O’Brien.